Zusammenfassung
Obwohl erst seit wenigen Jahren im Brennpunkt wissenschaftlichen Interesses, werden Negativsymptome schon lange beschrieben. Zwar besteht noch keine völlige Übereinkunft darüber, wer die erste Beschreibung negative Symptome lieferte, doch wird am häufigsten John Hughlings Jackson (1875) genannt, der sie vor mehr als 100 Jahren als primäres Defizit der Schizophrenie beschrieb. Er stellte zur Diskussion, daß negative Symptome auf eine primäre, nichtpathologische Läsion zurückgehen. Die Positivsymptomatik schizophrener Patienten beruhte seiner Ansicht nach auf einem Releasephänomen oder der Aufhebung einer Hemmung.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Andreasen NC (1982a) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788
Andreasen NC (1982b) Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 39: 789–794
Andreasen NC (1983) The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City
Andreasen NC (1984) The Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City
Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S (1990) Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch Gen Psychiatry 47: 615–621
Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative versus symptoms in schizophrenia. Psychopharmacology 72: 17–19
Arndt S, Alliger RJ, Andreasen NC (1991) The distinction of positive and negative symptoms: the failure of a two–dimensional model. Br J Psychiatry 158: 317–322
Bleuler E (1950) Dementia praecox or the group of schicophreniacs. Translated by Zinkin J. International Universities Press, New York
Breier A, Wolkowitz OM, Doran AR, Roy A, Boronow J, Hommer DW, Pickar D (1987) Neuroleptic responsivity of positive and negative symptoms in schizophrenia. Am J Psychiatry 144: 1549–1555
Carpender WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophrenia Bull 11: 440–447
Clark NL, Ray TS, Ragland RD (1963) Chlorpromazine in chronic schizophrenic women: rate of onset and rate of dissipation of drug effects. Psychosom Med 25: 212–217
Coryell WH, Kelly MW, Perry PJ, Miller DD (1990) Haloperidol plasma levels and acute clinical in schizophrenia. J Clin Psychopharmacol 10: 397–402
Crow TJ (1980) Molecular pathology of schizophrenia; more than one disease process? Br Med J 280: 66–68
Docherty JP, Van Kämmen DP, Siris SG et al. (1978) Stages of onset of schizophrenic psychosis. Am J Psychiatry 135: 420–426
Fischer-Cornelssen KA, Ferner UJ (1976) An example of european multicenter trials: multi-spectral analysis of clozapine. Psychopharmacol Bull 12: 34–39
Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456
Gur RE, Mozley PD, Resnick SM et al. (1991) Relations among clinical scales in schizophrenia. Am J Psychiatry 148: 472–478
Jackson JH (1875) On temporary mental disorders after epileptic paroxysms. West Riding Lunatic Asylum Medical Report 5: 105–129
Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1979) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1: 848–851
Kane J, Honigfeld G, Singer J et al. (1988) Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796
Kraepelin E (1919) Dementia praecox and paraphrenia. Barclay RB (ed) Livingston, Edinburgh Marks RC, Luchins DJ (1990) Relationship between brain imaging findings in schizophrenia and psychopathology. A review of the literature relating to positive and negative symptoms. Mod Probl Pharmacopsychiatry 24: 89–123
Meitzer HY (1991) Pharmacologic treatment of negative symptoms. In negative schizophrenic symptoms: pathophysiology and clinical implications. Greden JF, Tandon R (eds) American Psychiatric, Washington, DC Meitzer HY, Bastani B, Young Kwon K et al. (1989) A prospective study of clozapine in treatment–resistant schizophrenic patients; I. preliminary report. Psychopharmacology 99: S68–S72
Meitzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338
Naber D, Albus M, Burke H et al. (1985) Neuroleptic withdrawal in chronic schizophrenia: clinical and endocrine variables relating to psychopathology. Psychiatry Res 16: 207–219
Serafatinides EA, Collins S, Clark MI (1972) Haloperidol, clopenthixol and chlorpromazine in chronic schizophrenia. J Nerv Ment Dis 154: 31–42
Siris SG, Morgan V, Fagerstrom R et al. (1987) Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry 44: 533–539
Tandon R, Goldman RS, Goodson J, Greden JF (1990) Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychioatry 27: 1323–1326
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Miller, D. (1992). Negative Symptome und therapeutische Strategien bei Schizophrenie. In: Rifkin, A., Osterheider, M. (eds) Schizophrenie — aktuelle Trends und Behandlungsstrategien. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77843-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-77843-8_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-56014-2
Online ISBN: 978-3-642-77843-8
eBook Packages: Springer Book Archive